SunRISe-4
Brief description of study
The study is being conducted to research if an investigational drug delivery system (gemcitabine/TAR-200) in combination with intravenous cetrelimab and intravenous cetrelimab alone can improve the results of radical cystectomy for participants with muscle invasive bladder cancer.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
